Serum Gelatinases Levels in Multiple Sclerosis Patients during 21 Months of Natalizumab Therapy

Massimiliano Castellazzi, Tiziana Bellini, Alessandro Trentini, Serena Delbue, Francesca Elia, Matteo Gastaldi, Diego Franciotta, Roberto Bergamaschi, Maria Cristina Manfrinato, Carlo Alberto Volta, Enrico Granieri, Enrico Fainardi

Research output: Contribution to journalArticlepeer-review

Abstract

Background. Natalizumab is a highly effective treatment approved for multiple sclerosis (MS). The opening of the blood-brain barrier mediated by matrix metalloproteinases (MMPs) is considered a crucial step in MS pathogenesis. Our goal was to verify the utility of serum levels of active MMP-2 and MMP-9 as biomarkers in twenty MS patients treated with Natalizumab. Methods. Serum levels of active MMP-2 and MMP-9 and of specific tissue inhibitors TIMP-1 and TIMP-2 were determined before treatment and for 21 months of therapy. Results. Serum levels of active MMP-2 and MMP-9 and of TIMP-1 and TIMP-2 did not differ during the treatment. The ratio between MMP-9 and MMP-2 was increased at the 15th month compared with the 3rd, 6th, and 9th months, greater at the 18th month than at the 3rd and 6th months, and higher at the 21st than at the 3rd and 6th months. Discussion. Our data indicate that an imbalance between active MMP-9 and active MMP-2 can occur in MS patients after 15 months of Natalizumab therapy; however, they do not support the use of serum active MMP-2 and active MMP-9 and TIMP-1 and TIMP-2 levels as biomarkers for monitoring therapeutic response to Natalizumab.

Original languageEnglish
Article number8434209
JournalDisease Markers
Volume2016
DOIs
Publication statusPublished - 2016

ASJC Scopus subject areas

  • Biochemistry, medical
  • Clinical Biochemistry
  • Molecular Biology
  • Genetics

Fingerprint Dive into the research topics of 'Serum Gelatinases Levels in Multiple Sclerosis Patients during 21 Months of Natalizumab Therapy'. Together they form a unique fingerprint.

Cite this